Vyrix Pharmaceuticals Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Merger of Eq.

  • Financing Rounds
  • 2

Vyrix Pharmaceuticals General Information

Description

Developer of pharmaceutical products. The company engages in developing and commercializing late-stage prescription pharmaceuticals. It develops Zertane™, an oral drug in late stage development as a proprietary treatment for premature ejaculation. It is also developing a combination product with Zertane and an erectile dysfunction product to address co-morbid PE and erectile dysfunction.

Contact Information

Website
www.vyrixpharma.com
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • 5445 DTC Parkway
  • Suite 925
  • Greenwood Village, CO 80111
  • United States
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Acquirer
Aytu Biopharma
Corporate Office
  • 5445 DTC Parkway
  • Suite 925
  • Greenwood Village, CO 80111
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Vyrix Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Vyrix Pharmaceuticals‘s full profile, request access.

Request a free trial

Vyrix Pharmaceuticals Patents

  • 5

    Total Documents Applications and Grants

  • Total Patents Families

  • 2

    Granted

  • Pending

  • Expiring in next 12 mo

Vyrix Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-2677691-C Reducing side effects of tramadol Inactive 12-Feb-2007
CA-2677690-C Treatment of comorbid premature ejaculation and erectile dysfunction Inactive 12-Feb-2007
CA-2677690-A1 Treatment of comorbid premature ejaculation and erectile dysfunction Active 12-Feb-2007
CA-2677691-A1 Reducing side effects of tramadol Active 12-Feb-2007
JP-5550101-B2 Use of tramadol and a pde inhibitor in the manufacture of a drug that reduces the side effects of tramadol Inactive 12-Feb-2007 A61K31/519
To view Vyrix Pharmaceuticals’s complete patent history, request access »

Vyrix Pharmaceuticals Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Vyrix Pharmaceuticals‘s full profile, request access.

Request a free trial

Vyrix Pharmaceuticals FAQs

  • When was Vyrix Pharmaceuticals founded?

    Vyrix Pharmaceuticals was founded in 2013.

  • Where is Vyrix Pharmaceuticals headquartered?

    Vyrix Pharmaceuticals is headquartered in Greenwood Village, CO.

  • What industry is Vyrix Pharmaceuticals in?

    Vyrix Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Vyrix Pharmaceuticals a private or public company?

    Vyrix Pharmaceuticals is a Private company.

  • What is Vyrix Pharmaceuticals’s current revenue?

    The current revenue for Vyrix Pharmaceuticals is .

  • Who are Vyrix Pharmaceuticals’s investors?

    Ampio Pharmaceuticals has invested in Vyrix Pharmaceuticals.

  • Who acquired Vyrix Pharmaceuticals?

    Vyrix Pharmaceuticals was acquired by Aytu Biopharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »